Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 819

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 819
---
 |                                    |

<div align='center'>F-63</div>

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

Series C Preferred Stock warrants

In connection with the Series C Preferred Stock private placement, the Company issued 2,504Series C Agent Warrants. The Series C Agent Warrants have an exercise price of $ 1,000per share, provide for a cashless exercise feature, and are exercisable for a period of four years from August 19, 2020. The Series C Preferred Stock issuable upon exercise of the Series C Agent Warrants is convertible into shares of common stock in the same manner as each respective underlying series of outstanding Series C Preferred Stock and will be entitled to the same dividend rights as each respective series.

The following table sets forth changes in outstanding Series C Agent Warrants:

|                                   |     | BalanceJune 30,2023 |       |     | Number ofWarrantsIssued |   |     | Number ofWarrantsExercised |   |     | Balance,December 31,2023 |       |     | Conversionprice$ |       |
| Preferred SeriesC-1Agent Warrants |     |                     | 1,929 |     |                         | — |     |                            | — |     |                          | 1,929 |     |                  | 58.00 |
| Preferred SeriesC-2Agent Warrants |     |                     |   219 |     |                         | — |     |                            | — |     |                          |   219 |     |                  | 60.70 |
| Preferred SeriesC-3Agent Warrants |     |                     |   296 |     |                         | — |     |                            | — |     |                          |   296 |     |                  | 57.50 |
|                                   |     |                     | 2,444 |     |                         | — |     |                            | — |     |                          | 2,444 |     |                  |       |

The following table summarizes the Company’s outstanding Series C Agent Warrants as of December 31, 2023:

| Series C Agent Warrants |     | Number |       |     | Conversionprice$ |       |     | Number ofconversionshares(in thousands) |    |     | Cumulativecommon